Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib
The common painkiller, ibuprofen, may boost the likelihood of heart problems in high risk patients who have osteoarthritis, suggests research published ahead of print in the Annals of the Rheumatic Diseases.
Previous studies have suggested that ibuprofen interferes with the effects of aspirin.
The research team compared the cardiovascular health over one year of more than 18,000 patients aged over 50 with osteoarthritis.
The patients were taking part in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET).
They were taking either high dose (400 mg a day) lumiracoxib, a type of drug known as a cyclo-oxygenase (COX-2) inhibitor, or ibuprofen (800 mg three times a day), or naproxen (500 mg twice daily), both of which are traditional non-steroidal anti-inflammatory drugs (NSAIDs).
No comments:
Post a Comment